Bioiberica: A boost to the companyIn April, Luis Solera assumes the position of CEO at Barcelona-based biotech Bioiberica. He joins from LIPSA, a leading family business in the oils and fats sector. more ➔
Karolinska Development: Changes at the topFollowing the resignation of erstwhile CEO Jim Van heusden, Karolinska Development has promoted Viktor Drvota to the position of head of the company. Drvota held the position of Chief Investment Officer … more ➔
e-Therapeutics: Newly in chargeAIM-listed drug discovery company e-Therapeutics plc has a new head. In early April, Raymond Barlow took over as Chief Executive Officer. more ➔
Domainex: Navigating the growthDomainex has a new Executive Chairman: Timo Veromaa has been appointed to the Board of the British drug discovery services company. more ➔
Hansa Medical: Taking charge of medical...Hansa Medical, Lund-based developer of novel immunomodulatory enzymes, has recruited Sam Agus as Chief Medical Officer. Agus joins from H. Lundbeck AS, where he was Chief Specialist, Medical Affairs … more ➔
Crescendo Biologics: Aid for late-stage...Cambridge-based immuno-oncology developer Crescendo Biologics had named Philip Bland-Ward as its Chief Scientific Officer. He joins Crescendo from Kymab where he was responsible for leading its most … more ➔
EFPIA: Engaging for pharma innovationIn April, Nathalie Moll has taken on her new job as Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Moll is also Secretary General of Europe’s largest … more ➔
Endomag: Going beyond the horizonsCancer healthcare company Endomag, founded in 2007 as a spin-out from the University College London (UCL) and the University of Houston, has appointed Peter Keen as non-executive director. Keen will … more ➔
Dentons: All about taxes?? Dentons has announced the cooptation of Julien Le Guyader as partner in the Life Sciences Group of the Paris Office. Le Guyader has been a part of ?? Dentons since 2014. more ➔
Asit biotech: Expertise in vaccinesBelgian clinical-stage immunotherapy developer Asit biotech has appointed Gerd Zettlmeissl as its new Chairman of the Board. Zettlmeissl has been independent director of the company since 2011 … more ➔
